Data Visualization•8 min read•Updated 2026-04-03

    GLP-1 Drug Pipeline Visual: Every Weight Loss Medication in Development (2026)

    Visual map of every GLP-1 and weight loss medication currently in clinical trials, from Phase 1 through FDA approval. See what is coming next after semaglutide and tirzepatide.

    More on Data Visualization

    View all Data Visualization articles

    Next-Gen Drugs

    Future medications

    Retatrutide Guide

    Triple agonist

    Pipeline Overview

    Over a dozen weight loss medications are in clinical development. The next 2-3 years will bring oral options, triple agonists, and combination therapies. Meanwhile, semaglutide ($99/mo) and tirzepatide ($125/mo) are available now through Trimi.

    Drug Pipeline Map

    Retatrutide (Eli Lilly)

    Triple: GLP-1/GIP/Glucagon

    Phase 32027-2028
    24%+

    weight loss

    Orforglipron (Eli Lilly)

    Oral GLP-1 agonist

    Phase 32026-2027
    14-15%

    weight loss

    Survodutide (Boehringer)

    Dual: GLP-1/Glucagon

    Phase 32027-2028
    18-19%

    weight loss

    CagriSema (Novo Nordisk)

    Semaglutide + Cagrilintide

    Phase 32027
    22-25%

    weight loss

    Amycretin (Novo Nordisk)

    Oral: GLP-1/Amylin

    Phase 22028-2029
    13% (Phase 1)

    weight loss

    Pemvidutide (Altimmune)

    Dual: GLP-1/Glucagon

    Phase 22028+
    15%

    weight loss

    Pipeline data as of April 2026. Approval timelines are estimates and subject to change based on trial results and FDA review.

    Available Now at Trimi

    Semaglutide

    $99/mo

    FDA-approved. Available now.

    Tirzepatide

    $125/mo

    FDA-approved. Available now.

    Retatrutide

    Ask us

    Compounded. Ask about availability.

    Medical Disclaimer: Pipeline drugs are investigational and not yet FDA-approved for weight loss. This information is for educational purposes. Consult your provider about currently available options.

    Frequently Asked Questions

    What weight loss drugs are coming after Wegovy and Mounjaro?

    Several next-generation drugs are in development: retatrutide (triple agonist, Phase 3), orforglipron (oral GLP-1, Phase 3), amycretin (oral dual agonist, Phase 2), survodutide (dual agonist, Phase 3), and CagriSema (combination, Phase 3). Multiple oral options are expected by 2027-2028.

    When will retatrutide be FDA approved?

    Retatrutide is in Phase 3 trials (TRIUMPH program) with results expected in 2026-2027. If successful, FDA approval could come in late 2027 or 2028. Compounded versions may be available sooner through providers like Trimi.

    Will oral GLP-1 pills replace injections?

    Oral options like orforglipron and amycretin are showing promising results. While convenience is higher, early data suggests injectable forms may still produce slightly higher weight loss. Both forms will likely coexist to serve different patient preferences.

    Which pipeline drug looks most promising?

    Retatrutide has shown the highest weight loss in trials to date (24%+ at 48 weeks). Amycretin is notable as an oral medication matching injectable GLP-1 efficacy. CagriSema combines two proven compounds for potentially enhanced results.

    Why Wait? Start Treatment Today

    Compounded semaglutide from $99/mo or tirzepatide from $125/mo.

    View Treatment Options

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What does the current clinical evidence support for GLP-1-based weight management?

    GLP-1 receptor agonists (semaglutide, tirzepatide) have Phase 3 RCT evidence for chronic weight management in adults with BMI ≥30 or BMI ≥27 with a weight-related comorbidity. Trimi offers compounded preparations of the same active ingredients at $99/month (semaglutide) and $125/month (tirzepatide) on the annual plan, prepared per individual prescription by 503A community sterile compounding pharmacies and reviewed by a US-licensed clinician through Beluga Health's 50-state physician network. Compounded preparations are not themselves FDA-approved as drugs; the active ingredients are FDA-approved in the corresponding brand finished products. Eligibility is determined by a licensed clinician.

    Phase 3 RCT evidence base: STEP 1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SELECT (NEJM 2023), FLOW (NEJM 2024)
    Trimi pricing: $99/month semaglutide / $125/month tirzepatide on annual plan
    Clinical review: Dr. Asad Niazi, MD MPH via Beluga Health 50-state network

    Key Takeaways

    • Compounded semaglutide and compounded tirzepatide are prepared per individual prescription by 503A community sterile compounding pharmacies (VialsRx — Texas State Board pharmacy license #35264 — and GreenwichRx). The active ingredients (semaglutide, tirzepatide) are FDA-approved in the corresponding brand finished products (Wegovy / Ozempic and Zepbound / Mounjaro respectively). Compounded preparations are not themselves FDA-approved as drugs.
    • Eligibility for GLP-1 treatment is determined by a licensed clinician: BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease). Contraindications include personal/family history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, severe gastrointestinal disease, severe renal impairment, pregnancy, and breastfeeding.
    • Common GLP-1 receptor agonist adverse effects include nausea, vomiting, diarrhea, constipation, and gallbladder events. Most are mild-to-moderate and concentrated during dose escalation. Severe gastrointestinal symptoms causing dehydration can increase acute kidney injury risk and should be reported to the prescribing clinician.
    • Trimi's clinical review is coordinated by Dr. Asad Niazi, MD MPH through Beluga Health's 50-state physician network. Trimi pricing: $99/month for compounded semaglutide and $125/month for compounded tirzepatide on the annual plan; flat across all prescribed doses within whichever plan, with no enrollment / consultation / shipping fees.
    • This is general information based on the cited sources, not medical advice. Treatment decisions require evaluation by a licensed clinician familiar with your individual medical history.

    Medically Reviewed

    TMRT

    Trimi Medical Review Team

    Clinical review workflow for GLP-1 safety, dosing, and access content

    Team-based medical review process documented in Trimi's Medical Review Policy

    Last reviewed: November 8, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Trimi Medical Review Team, Clinical review workflow for GLP-1 safety, dosing, and access content

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    — Robyn Lynn CurtisFacebook
    Amazing company and care team support! Fast response time, no hidden fees and they actually care enough to work with you and your needs on your weight loss journey. Down 12.5 pounds in 2 months!

    Outcome: Down 12.5 lbs in 2 months

    — Sarah MillerFacebook
    See all community reviews →

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Garvey WT, Mechanick JI, Brett EM, et al. (2024). American Association of Clinical Endocrinology / American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocrine Practice.Read StudyDOI: 10.4158/EP161365.GL
    2. American Heart Association (2021). Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation.Read StudyDOI: 10.1161/CIR.0000000000000973
    3. Apovian CM, Aronne LJ, Bessesen DH, et al. (2015). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism.Read StudyDOI: 10.1210/jc.2014-3415

    Was this article helpful?

    Keep Reading

    Data Visualization

    GLP-1 Weight Loss Results by Medication: Visual Data Comparison

    Interactive visual comparison of weight loss results across semaglutide, tirzepatide, and retatrutide from clinical trials and real-world data.

    10 minRead More
    Data Visualization

    GLP-1 Medication Decision Tree: Which Weight Loss Drug Is Right for You?

    Interactive decision guide to help you choose between semaglutide, tirzepatide, and retatrutide based on your goals, health conditions, budget, and preferences.

    10 minRead More
    GLP-1 Medications

    How Retatrutide Works

    Retatrutide produced up to 24% weight loss in Phase 2 trials. See dose-response data, comparison with semaglutide and tirzepatide, timeline projections, and FDA approval outlook.

    10 minRead More
    Data Visualization

    GLP-1 Weight Loss Timeline: Week-by-Week Visual Guide from Day 1 to Month 12

    Visual timeline showing what to expect each week and month on GLP-1 medications. Weight loss milestones, side effect patterns, and body changes mapped out.

    10 minRead More

    Start your GLP-1 journey — from $99/mo

    Get Started